What is the history of Von Willebrand Disease?

Von Willebrand Disease was first described in 1926 by Finnish physician Erik von Willebrand, who identified it while investigating a family with a unique bleeding disorder on the Åland Islands. Since its discovery, medical understanding of Von Willebrand Disease has evolved from a simple "pseudo-hemophilia" to a complex, multi-type genetic condition involving the deficiency or dysfunction of the von Willebrand factor protein.

When was Von Willebrand Disease first discovered?

The history of Von Willebrand Disease began in 1924, when Erik von Willebrand, a Finnish internist, examined a five-year-old girl named Hjördis Sjöberg. She suffered from severe mucosal bleeding, a trait shared by several of her siblings. In 1926, he published his findings, distinguishing this condition from hemophilia because it affected both males and females and involved prolonged bleeding times rather than just clotting factor deficiencies. At the time, he termed the condition "pseudo-hemophilia," not realizing it was a distinct genetic entity.

How has our understanding of Von Willebrand Disease evolved?

For decades, the medical community struggled to differentiate Von Willebrand Disease from other bleeding disorders. A major breakthrough occurred in the 1950s when researchers identified that patients with the condition lacked a specific plasma factor necessary for platelet adhesion. By the 1970s, scientists successfully isolated the von Willebrand factor (VWF) protein, which acts as a "glue" to help platelets stick to injured blood vessel walls. This discovery allowed for the classification of Von Willebrand Disease into distinct types (Type 1, 2, and 3), which help clinicians tailor treatment based on whether the protein is simply low in quantity or structurally defective.

What were the major milestones in treatment development?

The evolution of therapy for Von Willebrand Disease has significantly improved patient outcomes and quality of life over the last century:

• 1970s: The development of cryoprecipitate and later, factor VIII concentrates, provided the first effective replacement therapies for severe cases.


• 1980s: The introduction of Desmopressin (DDAVP) revolutionized care for Type 1 patients by stimulating the release of stored von Willebrand factor from the body's own cells.


• 1990s-Present: Modern recombinant (lab-engineered) VWF concentrates have become the gold standard, offering a safer alternative to plasma-derived products by eliminating the risk of blood-borne viral transmission.

How have genetics and patient advocacy changed the landscape?

Modern genetic testing has transformed the diagnosis of Von Willebrand Disease, allowing for precise identification of mutations in the VWF gene on chromosome 12. This level of detail has helped correct historical misconceptions—specifically, that the condition was merely a mild form of hemophilia. Today, patient advocacy groups, including the community of 184 individuals currently connected through DiseaseMaps.org, play a vital role in raising awareness. By sharing lived experiences, these communities have helped move the focus from purely clinical metrics to the holistic management of living with a chronic bleeding disorder.

Next steps

• Consult a hematologist specializing in bleeding disorders to discuss your specific VWF type and treatment plan.


• Request genetic counseling if you are planning a family, as understanding the inheritance pattern (autosomal dominant or recessive) is crucial.


• Join the DiseaseMaps.org community to connect with others who share your journey and learn about current research.


• Keep a "bleed diary" to document episodes, which helps your medical team monitor the effectiveness of your preventative or acute therapies.

Medical disclaimer: This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.

References

• NIH GARD: Von Willebrand Disease (https://rarediseases.info.nih.gov/)


• Orphanet: Rare Disease Database (https://www.orpha.net/)


• OMIM: Online Mendelian Inheritance in Man (https://omim.org/)


• National Hemophilia Foundation: VWD History and Clinical Guidelines (https://www.hemophilia.org/)